Cipla clarifies on promoter stake sale; for personal and philanthropic purposes

Drugmaker Cipla has said that its promoters Dr Y K Hamied, Chairman and MK Hamied, Vice Chairman who are Non-Executive Directors, have sold 2.5 percent stake in the company for “personal purposes including philanthropy”.

According to reports, the sale would bring in about Rs 1800-odd crore.

In a clarification to the Bombay Stock Exchange, a note quoting Samina Hamied, Cipla’s Executive Vice Chairperson said, 2,01,69,756 shares (representing 2.5 percent of the total issued and paid-up share capital of the company) had been sold today.

Post transaction, the promoter group will continue to hold 34.23 percent in the company, the note said, adding that they remain fully committed and invested in the future of Cipla Limited. “The senior promoters who are both in their eighties, intend to use the funds generated from this sale for personal purposes including philanthropy. The promoter group does not plan to sell any further shares in the foreseeable future,” the note said.

“Cipla is being led by the third generation of the founding family. As a family, we are fully committed to the organisation. I will continue to carry forward the Cipla legacy and drive the company into the future – to achieve new goals and scale new heights,” the note from Samina, daughter of MK Hamied said.

Related Posts

  • Pharma
  • July 26, 2024
  • 126 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 125 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD